<p>Bright Minds Biosciences Inc.（納斯達克代碼：DRUG - 獲取免費報告）的股票在目前覆蓋該公司的八家券商中獲得了平均 “買入” 評級，MarketBeat.com 報道。一位研究分析師給予該股票持有評級，六位分析師給予買入評級，還有一位分析師對該公司給予強烈買入評級。在過去一年中，覆蓋該股票的券商的平均一年目標價為 82.50 美元。</p>
<ul>
<li>生物科技處於邊緣：兩隻潛力巨大的股票</li>
</ul>
<p>DRUG 最近成為幾份研究報告的主題。Chardan Capital 在 11 月 19 日的研究報告中將 Bright Minds Biosciences 的股票評級上調至 “強烈買入”。Zacks Research 在 12 月 2 日的報告中將 Bright Minds Biosciences 的股票評級從 “強烈買入” 下調至 “持有”。Cantor Fitzgerald 在 12 月 1 日的報告中重申了對 Bright Minds Biosciences 股票的 “增持” 評級。Wall Street Zen 在 10 月 3 日的研究報告中將 Bright Minds Biosciences 的股票評級從 “持有” 下調至 “賣出”。最後，BTIG Research 在 9 月 8 日的研究報告中開始覆蓋 Bright Minds Biosciences，給予 “買入” 評級和 72.00 美元的價格目標。</p>
<p><strong>獲取我們關於 DRUG 的最新股票報告</strong></p>
<h2>對 Bright Minds Biosciences 的對沖基金看法</h2>
<ul>
<li>Bright Minds Biosciences 股票暴漲近 1500%</li>
</ul>
<p>機構投資者最近調整了對該公司的持股。Braidwell LP 在第三季度以約 18422000 美元的估值收購了 Bright Minds Biosciences 的新頭寸。Vivo Capital LLC 在第三季度將其在 Bright Minds Biosciences 的股份增加了 99.4%。Vivo Capital LLC 現在擁有 501,617 股該公司的股票，估值為 30428000 美元，此前在此期間又收購了 250,045 股。Balyasny Asset Management L.P. 在第三季度以約 11339000 美元的估值收購了 Bright Minds Biosciences 的新頭寸。Millennium Management LLC 在第一季度將其在 Bright Minds Biosciences 的股份增加了 376.9%。Millennium Management LLC 現在擁有 192,557 股該公司的股票，價值 6946000 美元，此前在此期間又收購了 152,178 股。最後，Adage Capital Partners GP L.L.C. 在第一季度將其在 Bright Minds Biosciences 的股份增加了 50.9%。Adage Capital Partners GP L.L.C. 現在擁有 200,000 股該公司的股票，價值 7214000 美元，此前在上個季度又購買了 67,500 股。機構投資者持有該公司 40.52% 的股票。</p>
<h2>Bright Minds Biosciences 價格表現</h2>
<p>DRUG 週四開盤價為 88.83 美元。該公司的市值為 6.9195 億美元，市盈率為-95.51，貝塔值為-6.22。Bright Minds Biosciences 的 52 周低點為 23.17 美元，52 周高點為 97.75 美元。該公司的 50 日移動平均線為 65.84 美元，200 日移動平均線為 47.14 美元。</p>
<h2>關於 Bright Minds Biosciences</h2>
<p>（獲取免費報告）</p>
<p>Bright Minds Biosciences Inc. 是一家生物技術公司，開發治療藥物以改善美國患者的生活，特別是那些患有嚴重和改變生活的疾病。其選擇性 5-HT 受體激動劑的產品組合包括用於治療癲癇、疼痛和神經精神疾病的 5-HT2C、5-HT2A 和 5-HT2C/A，以及完成針對未披露癲癇病的 1 期試驗的 BMB-101。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Bright Minds Biosciences</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>券商排名在股票選擇中的重要性</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的重大催化劑</li>
<li>股票情緒分析：如何運作</li>
<li>Upwork 能否維持其復甦？看漲和看跌的理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Bright Minds Biosciences 嗎？</h2>
<p>在你考慮 Bright Minds Biosciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bright Minds Biosciences 並不在名單上。</p>
<p>雖然 Bright Minds Biosciences 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

DRUG

<p>Bright Minds Biosciences Inc.（納斯達克代碼：DRUG）獲得了八家券商的一致 “買入” 評級，平均一年目標價為 82.50 美元。機構投資者顯著增加了持股，推動股價上漲近 1500%。該公司開發針對嚴重疾病的治療藥物，市值為 6.9195 億美元。儘管獲得了 “買入” 評級，但頂級分析師建議其他股票可能提供更好的投資機會</p>

<p>Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) have received an average rating of &#34;Buy&#34; from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $82.50.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc.（納斯達克代碼：DRUG - 獲取免費報告）的股票在目前覆蓋該公司的八家券商中獲得了平均 “買入” 評級，MarketBeat.com 報道。一位研究分析師給予該股票持有評級，六位分析師給予買入評級，還有一位分析師對該公司給予強烈買入評級。在過去一年中，覆蓋該股票的券商的平均一年目標價為 82.50 美元。</p>
</div><ul>
<li>Biotechs on the Brink: 2 Stocks With Huge Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技處於邊緣：兩隻潛力巨大的股票</li>
</ul>
</div><p>DRUG has been the topic of several recent research reports. Chardan Capital raised shares of Bright Minds Biosciences to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 19th. Zacks Research downgraded shares of Bright Minds Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, December 2nd. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Bright Minds Biosciences in a report on Monday, December 1st. Wall Street Zen downgraded shares of Bright Minds Biosciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Friday, October 3rd. Finally, BTIG Research began coverage on Bright Minds Biosciences in a research report on Monday, September 8th. They issued a &#34;buy&#34; rating and a $72.00 price target for the company.</p>
<div class="lb-trans"><p>DRUG 最近成為幾份研究報告的主題。Chardan Capital 在 11 月 19 日的研究報告中將 Bright Minds Biosciences 的股票評級上調至 “強烈買入”。Zacks Research 在 12 月 2 日的報告中將 Bright Minds Biosciences 的股票評級從 “強烈買入” 下調至 “持有”。Cantor Fitzgerald 在 12 月 1 日的報告中重申了對 Bright Minds Biosciences 股票的 “增持” 評級。Wall Street Zen 在 10 月 3 日的研究報告中將 Bright Minds Biosciences 的股票評級從 “持有” 下調至 “賣出”。最後，BTIG Research 在 9 月 8 日的研究報告中開始覆蓋 Bright Minds Biosciences，給予 “買入” 評級和 72.00 美元的價格目標。</p>
</div><p><strong>Get Our Latest Stock Report on DRUG</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 DRUG 的最新股票報告</strong></p>
</div><h2>Hedge Funds Weigh In On Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>對 Bright Minds Biosciences 的對沖基金看法</h2>
</div><ul>
<li>Bright Minds Biosciences Stock Surges Almost 1,500%</li>
</ul>
<div class="lb-trans"><ul>
<li>Bright Minds Biosciences 股票暴漲近 1500%</li>
</ul>
</div><p>Institutional investors have recently modified their holdings of the company. Braidwell LP acquired a new position in shares of Bright Minds Biosciences during the third quarter valued at about $18,422,000. Vivo Capital LLC increased its stake in Bright Minds Biosciences by 99.4% during the third quarter. Vivo Capital LLC now owns 501,617 shares of the company's stock valued at $30,428,000 after acquiring an additional 250,045 shares during the period. Balyasny Asset Management L.P. acquired a new position in Bright Minds Biosciences in the 3rd quarter valued at approximately $11,339,000. Millennium Management LLC lifted its position in shares of Bright Minds Biosciences by 376.9% in the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company's stock worth $6,946,000 after acquiring an additional 152,178 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its holdings in shares of Bright Minds Biosciences by 50.9% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 200,000 shares of the company's stock worth $7,214,000 after purchasing an additional 67,500 shares in the last quarter. Institutional investors own 40.52% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近調整了對該公司的持股。Braidwell LP 在第三季度以約 18422000 美元的估值收購了 Bright Minds Biosciences 的新頭寸。Vivo Capital LLC 在第三季度將其在 Bright Minds Biosciences 的股份增加了 99.4%。Vivo Capital LLC 現在擁有 501,617 股該公司的股票，估值為 30428000 美元，此前在此期間又收購了 250,045 股。Balyasny Asset Management L.P. 在第三季度以約 11339000 美元的估值收購了 Bright Minds Biosciences 的新頭寸。Millennium Management LLC 在第一季度將其在 Bright Minds Biosciences 的股份增加了 376.9%。Millennium Management LLC 現在擁有 192,557 股該公司的股票，價值 6946000 美元，此前在此期間又收購了 152,178 股。最後，Adage Capital Partners GP L.L.C. 在第一季度將其在 Bright Minds Biosciences 的股份增加了 50.9%。Adage Capital Partners GP L.L.C. 現在擁有 200,000 股該公司的股票，價值 7214000 美元，此前在上個季度又購買了 67,500 股。機構投資者持有該公司 40.52% 的股票。</p>
</div><h2>Bright Minds Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Bright Minds Biosciences 價格表現</h2>
</div><p>DRUG opened at $88.83 on Thursday. The company has a market capitalization of $691.95 million, a PE ratio of -95.51 and a beta of -6.22. Bright Minds Biosciences has a fifty-two week low of $23.17 and a fifty-two week high of $97.75. The business has a 50-day moving average of $65.84 and a 200-day moving average of $47.14.</p>
<div class="lb-trans"><p>DRUG 週四開盤價為 88.83 美元。該公司的市值為 6.9195 億美元，市盈率為-95.51，貝塔值為-6.22。Bright Minds Biosciences 的 52 周低點為 23.17 美元，52 周高點為 97.75 美元。該公司的 50 日移動平均線為 65.84 美元，200 日移動平均線為 47.14 美元。</p>
</div><h2>About Bright Minds Biosciences</h2>
<div class="lb-trans"><h2>關於 Bright Minds Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.</p>
<div class="lb-trans"><p>Bright Minds Biosciences Inc. 是一家生物技術公司，開發治療藥物以改善美國患者的生活，特別是那些患有嚴重和改變生活的疾病。其選擇性 5-HT 受體激動劑的產品組合包括用於治療癲癇、疼痛和神經精神疾病的 5-HT2C、5-HT2A 和 5-HT2C/A，以及完成針對未披露癲癇病的 1 期試驗的 BMB-101。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Bright Minds Biosciences</li>
<li>The 3 Best Blue-Chip Stocks to Buy Now</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Bright Minds Biosciences</li>
<li>現在購買的三隻最佳藍籌股</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>券商排名在股票選擇中的重要性</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的重大催化劑</li>
<li>股票情緒分析：如何運作</li>
<li>Upwork 能否維持其復甦？看漲和看跌的理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFJVRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=DRUG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bright Minds Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Bright Minds Biosciences 嗎？</h2>
</div><p>Before you consider Bright Minds Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Bright Minds Biosciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bright Minds Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Bright Minds Biosciences 並不在名單上。</p>
</div><p>While Bright Minds Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Bright Minds Biosciences 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bright Minds Biosciences Inc.（納斯達克股票代碼：DRUG）被券商一致推薦為 “買入” 評級